NCT07669727Not yet recruiting
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
A Post Approval Single-arm Study Evaluating Transarterial Radioembolization Treatment for Hepatocellular Carcinoma Using Multicompartment Dosimetry Planning
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and effectiveness of treating a tumor using a different planning method called MCD for the FDA-Approved device, TheraSphere. TheraSphere Microspheres are microscopic radioactive glass spheres that deliver radiation therapy in the liver tissue where they are placed. This study investigates a procedure called multicompartment dosimetry (MCD). When using a multicompartment dosimetry approach, the doctor will look at images of the liver to see where there is tumor to determine where to treat. That area will be divided into "compartments" where the dose to tumor and the healthy liver are calculated separately. The goal of MCD is to give the tumor a higher radiation dose while protecting more of the healthy part of the liver. Traditional planning for the TheraSphere Microspheres procedure uses single compartment dosimetry (SCD) which treats the tumor and the healthy liver as one area so the dose is more evenly distributed and the dose to the tumor may be lower than with the MCD approach. The single compartment approach is standard and is well established however this research study is to see if giving TheraSphere Microspheres with an MCD planning method is safe and effective by evaluating the effect of radiation on the liver as well as how the tumor responds to higher doses
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 31 May 2028
- Lead sponsor
- Boston Scientific Corporation
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07669727
What you commit to
- Study type: Observational
- Planned participants: 140
- From 1 Jan 2027 to the primary completion date, 31 May 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or current ascites/encephalopathy
- Previous liver radiation, TACE, or systemic therapy for the disease
Other illness
- History of organ allograft including bone marrow
Other
- Macrovascular invasion
- Extrahepatic metastases
- Any significant comorbities or contraindications to TheraSphere
Who the study is looking for
- TheraSphere Microspheres treatment determined as the optimal therapy
- Have unresectable solitary HCC
- Treatment Naïve
- ECOG 0 or 1
- Adequate liver function
- Adequate renal and marrow function
- Negative pregnancy test and/or adequate contraception for the patient and his/her sexual partner
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.